Buena buys BAX 76.75: Baxter announces FDA approval of ADVATE with BAXJECT III Reconstitution System
Baxter International (NYSE:BAX) today announced that the US Food and Drug Administration (FDA) has approved a new reconstitution system for ADVATE (Antihemophilic Factor [Recombinant]). ADVATE and the diluent come pre-packaged in the new BAXJECT III ... ...
50 people liked this
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home